MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Congestive Heart Failure (CHF)
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)*
Organization & Developments: Intra-Cellular
Parents
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)*
Children
*Develops novel drugs for the treatment of diseases and disorders of the central nervous system - specifically, neuropsychiatric and neurological conditions such as schizophrenia, bipolar depression, and behavior disturbances associated with dementia
*Focused on the development of therapeutics for central nervous system (CNS) disorders
*ITCI’s inception came by way of leveraging technology from the lab of Nobel Laureate Dr. Paul Greengard.
2017: Intra-Cellular Therapies: Positive FDA Response Leads To A Rebound In Share Price - Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
2018: Intra-Cellular Therapies: Betting On A Safer Drug_seekingalpha.com
2019: Biotech Analysis Central Preview Series: Intra-Cellular Therapies_seekingalpha.com
2019: Buying Intra-Cellular Therapies On The Dip: Investment Thesis_seekingalpha.com
2019: Here's Why Intra-Cellular Therapies Rose as Much as 176.8% Today
2019: Intra-Cellular fingers a high placebo response explaining a PhIII failure as lead drug goes 1-and-1 in depression – Endpoints News
2019: Intra-Cellular Therapies: Forecasting Upcoming Approval_seekingalpha.com
2019: Intra-Cellular's Fantastic Day & A Santastic Offer_seekingalpha.com
2020: Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression
2020: Intra-Cellular Therapies: Another Growth Cycle Approaching
2020: Intra-Cellular: Label Expansion PDUFA Up Ahead
2021: Intra-Cellular: Substantial Unlocked Value In Caplyta Franchises
2022: Intra-Cellular Therapies: What Lies Ahead_seekingalpha.com
2022: Intra-Cellular: Hitting A Growth Inflection (Rating Upgrade)_ seekingalpha.com
2022: Intra-Cellular: Long-Term To Own With A Few FDA Approvals And Ability To Expandseekingalpha.com
2023: Intra-Cellular's Caplyta On Its Way To Being Mental Health Blockbuster (NASDAQ:ITCI)
2023: The Right Play On Intra-Cellular Therapies_ seekingalpha.com
2024: How Intra-Cellular surprised Wall Street by breaking character
2024: Intra-Cellular bolsters Caplyta data with another Phase III win
2024: Intra-Cellular Therapies Is On Fire
2024: Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
2024: Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
2024: Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data_ seekingalpha
2024: Intra-Cellular's unstoppable Caplyta nails another trial, this time for relapse prevention in schizophrenia
Jumps
*Key People: Intra-Cellular
Finance & Acquisitions: Intra-Cellular